331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, Deangelis L. 331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Annals Of Oncology 2016, 27: vi105. DOI: 10.1093/annonc/mdw367.09.Peer-Reviewed Original ResearchPhase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Kaley T, Nolan C, Omuro A, Wolfe J, Mellinghoff I, DeAngelis L. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2016, 34: 2046-2046. DOI: 10.1200/jco.2016.34.15_suppl.2046.Peer-Reviewed Original Research